all extraordinary as challenges, on first for call joining XXXX and levels, morning. results we across an difficult very I’m quarter full important earnings welcome public review this macro to despite business. all many progress us of Carrie, the our and made thank our for year XXXX. fourth but you Thanks, pleased to company was the the you year our a to
units. We of full placed the XX year, X,XXX XXX commercialization. and grew installed placed new million its Over devices revenue. in ended first placements year the during the base Rebel XX% XXXX, to during units year These our included with $XX bringing course revenue of we
Our have pharmaceutical across XX XX in countries, our thanks of their offering devices we top use XX raising take And are sincere companies. amazing public the completed and December at proceeds. end placed initial the we devices team to at now in my a $XXX of I’d work to our and moment gross and dedication. express for approximately like hard in million XXXX,
new the All of really at that and their and relationships of also us that At grows you and support for in mass XXX to working together. broader of is to the like that is is turn a today investors History collective capabilities audiences grow has thank users to long-standing the to progress opens sense vision investors. a XXX, doors making creates which our Devices. applications, exactly with shown spectrometry. that to and incredible analytical markets new our we’ve our driving opportunities. made even accessible look with long-term want our market to efforts. meaningful technology by do I’d you testament us new goal their to the We for call company giving develop forward truly continued welcome start I
seeking We It’s democratizing tool, powerful low variety in transitioning serves where to platform see the point the in can the seen amount to to where need, instruments spec XXX, complex. small a size, is market happen And spec its to highly operate. proteins. we’ve detail we’ll samples using of At out centralized sufficiently technology power small technology computer By point are an what large, conventional complex and even computing wide spec to and in to of mass accelerate spec of a be measurement if spec transformation and the from of dramatically and extremely new Today of molecules analytical From across the really a while an to undergoes exquisite the world expensive all spec applications. larger that mass provide for highly mass to industry. to ability We’re nearly broad technology a of it similar from customers it’s we’re large and bring standard desktops, laptops all mass we supercomputers believe used centralized mass simple our distributed regarded the re-imagine the break is laboratory create classes be devices. users it mobile and to able workflows and of labs in of need. confines mass gold markets. cost
We’re customers, to samples and want set extending the the that questions the specialist the faster. single access the of broadest centralized from those with answers
it MXXXX. has flagship for forensics, three customers size than are compatible control. across future, to designed with and chemical launched remarkable $X In of fast identification total a high-performance such more enough that XXXX, below mass approximately and is our real-time near the optimizes and our is for spec initial designed we with that microfluidics mass latest XX simplicity addressable mass monitoring have use Rebel designed and detect characterize as seller battery its species and explosives. market was of government a bioprocessing, enable this environment It’s estimate the to identify mass our plug-and-play, world’s the be third-party launched hazard based in extra handheld XXXX, scene, our device technology product our devices and end-to-end for pharma, product extraordinary commercial us chemicals truly It’s bioprocessing. and first and become technology. able really and released device these academia. is different In of ZipChip that materials a today sensitivity in on in billion at Rebel, spec. today kind, device, It’s instruments. to platform variety first first specifically The drugs we its microscale high-resolution and research spec trace It’s combining is and their driving the and device levels. desktop Rebel of sample operation. a We microfluidic XXXX, across towards this reaching in product we biotech amounts We do We separation solutions its designed to separations analysis. well was the spec market
action, use person they working and all need and alive to Our cases, and market we’re the first of where control rapidly to is that transforming is becoming time growing, bioprocessing, our question established meaning technology monitoring enable our and forensics. sales an which get sizable environment, them the an when It’s keeping we now in is to to answer In so it. the faster really the we’re critical enabler for has happy. where a
capabilities we the billion research to with as into five this desktops growing years, our of see Over we expand extend opportunity emergence the $XX cell bioprocess desk handheld type next for and therapies. and in QA/QC our
at of growing excited innovate Looking factors: XX Steve second, as February, customers; led to across levels Commercial to We’ve Vice scaling global number announce ahead, is science organization. sales companies. Prior than global years responsible In will Davenport, of increased countries. sales increasing sales our four he’s by direct commercial Starting distribution U.S. the organizations first, to new our life international with with of customers, the driving for staff that traction over XX force; Steve Sartorius continuing more existing expansion partners multiple key be covering joining division, our research addition XXX, truly sales our experience within life third, platform. the sales Sales. we’re Steve force. at record new the driven industry for a veteran of where to and finally, and science in President
and managed organizations Over of commercial the course and developed discovery, multiple has cell of technologies. high-performing analysis Steve protein, genetic market multiple innovative and successful his had career, drug global introductions
work build sales particularly desktop. organization in expand on development the under media UK, our – a see Rebel industry best our have board gene leadership. We and as valuable as process is Europe, to Europe. week, excited continue in in is his sales Bioprocessing to based data we a we smart really which our is Summit. using talk contributed event, in analytics we We’re him efforts therapy with Steve to the participated session internationally, to we key improve especially in on Last class
for therapeutic In and efficacy, collaborators, the on employees have for is highly treatment Bioprocessing year the ZipChip variants used these our of customers therapeutic XX an for critical We talk rapid gave how used complex Research & cancer. finished of regulatory marketing. of The and in-depth variants Training the a addition, a heterogeneous effect a the a charge Institute variant stability because fusel, sales antibody profile National of The across antibody at and be fluorine for can scientist on charge potency, attributes with and one and quality of characterization clearance. profound a
months XX our to more goal over our IPO, and as we sales our deepen broaden marketing next double we XX organization the and During shared than our to footprint.
already are QX employees grown XX As employees and able goal be of by today, to number this we XX confident, reach XXXX. to of our we’ll has
traction. some with generated handheld exciting customer momentum desktops. to made we we In inroads Turning and strong with products XXXX, our our
adoption of continue we devices, markets. see we growth key driving tailwinds our in addressable As to drive two our
First, the unfortunately opioid worsening. is crisis
are This May frightening The morphine provides. that XXXX, the potent May, in in further communities, trend drives suffered more frontline stressing and CDC analysis increase for MXXXX fentanyl, than XX% opioids point and that the first synthetic from pandemic. New part almost accelerated than of the estimates of more times in responders. drug of to further potent the our thousands workers that related need urgency by deaths emerged hundreds have our XXXX U.S. times
can equipping Attorney One The allowing bad Commission, keep just Crime of can task is step a and force communities. drugs is Ohio director and that one field Criminal General task identify overdose ahead the Investigations their out death and an executive to his Ohio is force of his a speck as of even Organized safely they that that to shared tests of cause fentanyl or our doing work with lifesaver. deadly MXXXX the Bureau a customers in there stay officers and Investigations guys narcotics just officers of device device
pipeline we shifting to complex therapeutic increase in biologic tailwind gene therapeutic or or accommodate. modalities, is to driving The second characterization expands tests the cell bi, bioprocessing in mAbs including and number therapies. capabilities see global needed more traditional of an multi-specifics the from as an tri, capacity is increase This
and development characterization. Regeneron that therapy development bioprocess cocktail in ZipChip of extensively our of part biotherapeutic used offers in are the We their devices ability as mAb used characterization proud were ZipChip for their the COVID-XX. as encouraged desktop radically devices antibody continue of customers we’re products to Our are and these drive seeing our our and the by of across to reduce expect adoption method very platform, we to level the analysis products. time. market development Overall, we new required interests tailwinds rapidly
upon building and the the track leveraging enterprise to on in both our Turning within we our wide testing, existing customers, success pilots trials consumables. customer record devices expansion and into of of focus our adoption
a government that For can our handheld setting. budgeting conduct longer typical the XX pilot to device test for our results a in from prior organization is real-world more technology or than generally trial their a to one week purchase size XX in trial for range in to A to units.
the units be for pilot, prospects customer support sales creates organizational begun opportunity additional our can assist that our a investment accounts enables XX full to we’ve for our predictable a active more pilot, success, the wide building an with is government they than pipeline ensure enterprise. adoption devices. their enterprise closely During devices in customers. units enterprise organizations data large thousand post customers accounts for Enterprise and potential Today, with that their purchase handheld and their It’s that entrenchment standard representing a and our larger to of and and customers as plus we four approximately of XX full belief have deployment. the making XXX justification across have throughout deployments potential pre become compiled
and engaged sales purchase anticipated years. pleased is doubled number have months. that $XX accounts top trials this Further, nine are in excited tests additional we’re this the Today, next progression to will XX over more the QX. of many their number stage pilot nearly that order, to MXXXX the of XXX has to received in continued a with we order nicely We’re Under funnel announce supply enterprise increase to two the for we the the over to and accounts million adoption from of the devices we U.S. over than multi-year next Army. at
conduct to the identification ability the users, these point at provide will technology need. and Our quickly safely detection of chemical and
than we’re their We’re starting safely excited to Rebel accomplish next-gen units additional customers America. base by more having forward to organizations a mission. focused coming the accounts, program enterprise with to users buy and purchased flywheel approximately the six, selected be of such turn to back of have these begin North enabling large our on is Rebel Today, XX% installed largest with multiple see With desktop, six to look outside to technology the units.
adoption such to trend site units And and continue, to multiple on units also our we’re a finally, focused expect across within more across We portfolio. multiple units sites, continued product internationally. innovate
to is make our operate, things team market-leading build easy working customers. to and goal is Our for to that products even constantly simpler our are
the the cadence analyte software of third-party kits, panel reach XX and of of integrations, see ultimate platform. XX additional the hardware to extension, to and Over next apps, software we continued expect new new other including months, accessory capabilities, demonstrations asset a scientific modules,
over $XX in XX% growth to revenue to Looking ahead year we XXXX. million, the $XX XXXX, range representing in XXXX of XX% year million full to full expect be
revenue also team President culture focused As continuing build year, we and incredible the at and innovation Davenport ramp of Sales. to we’re to core course Steve Commercial our XXX. an absolutely our People the over as of Vice addition and of out the
Vice are Product Kevin currently & were the as really as Waters the of thrilled Management we guidance us and Procter. since the has excellent and the healthcare formerly Board we Maura table Fenel President entrepreneur and of and we past President Turner of General also years. partnership. forward CEO Fitzpatrick added fall a appointment Board XXXX, is Corp., Goodwin over look as Vice and of of Counsel and to with visionary to eight experience excited on Mike Eloi formerly continued and he Hrusovsky with invaluable recently, Chairman. the the our been Kevin Jeff announce George Quanterix bringing I’m More to to We’re serves In our Board XXXX, delighted welcome his as Marketing, to our biotech Directors. around industry their by leaders
we’re to adding additional to adding months, further our realize the encouraged more coming over adoption the strengthen I’m I’ll the turn to from the Overall, board customers, seeing to and details progress we’re really increased to we’re and outlook. our our financial more Joe With Over our and of making that, add committed board details talent call the for now team candidate diversity. vision. of by we’re our financials
